22 of 60 (36.6%) patients experienced tumor regression, and the results showed that TIL infusion combined with anti-PD-L1 therapy prolonged the survival of chemotherapy-resistant metastatic in patients with osteosarcoma (49). Here, CD274 is linked to osteosarcoma.